Biolegend, 101909, APC anti-mouse CD25 Antibody, 25μg

CD25 is a 55 kD glycoprotein, also known as the low affinity IL-2Rα, Ly-43, p55, or Tac. It is expressed on activated T and B cells, thymocyte subset, pre-B cells, and T regulatory cells. In association with CD122 (IL-2Rβ) and CD132(common γ chain), CD25 forms the high affinity signaling IL-2 receptor.
25μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: IL-2-dependent BALB/c mouse helper T-cell clone HT-2
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser: Red Laser (633 nm)
Application Notes: Additional reported applications (for the relevant formats) include: in vitro blocking of IL-2 binding to low- and high-affinity receptors1,2, and immunohistochemical staining of acetone-fixed frozen sections. 3C7 antibody recognizes different epitope of PC61 antibody (Cat. No. 102002). The Ultra-LEAF™Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 101925 and 101926).
Application References(PubMed link indicates BioLegend citation): Ortega RG, et al. 1984. J. Immunol. 133:1970. (Block) Moreau JL, et al. 1987. Eur. J. Immunol. 17:929. (Block)
Product Citations: Laura C Burzynski et al. 2019. Immunity. 50(4):1033-1042 . PubMed Sohn HS, et al. 2022. Sci Adv. 8:eabo5284. PubMed Wang Y, et al. 2023. iScience. 26:106630. PubMed Yao RQ, et al. 2023. Mil Med Res. 10:27. PubMed Shen Z, et al. 2022. EBioMedicine. 85:104285. PubMed Zhu M, et al. 2022. Front Immunol. 13:1019248. PubMed Li X, et al. 2019. Mol Med Rep. 19:4195. PubMed Li X, et al. 2022. Nat Commun. 13:2794. PubMed Rosalia R, et al. 2013. Immunobiology. 218:851. PubMed Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed Andreas N, et al. 2021. Arthritis Res Ther. 23:222. PubMed Liu X, et al. 2021. eLife. 0.416666666666667. PubMed Gorczynski RM, et al. 2017. Immunology. 150:418. PubMed Levine LS, et al. 2021. Immunity. 54(4):829-844.e5. PubMed Ren HZ, et al. 2022. J Clin Transl Hepatol. 10:1138. PubMed Fujiwara H, et al. 2021. Nat Immunol. 22:1440. PubMed Shi R, et al. 2022. Theranostics. 12:875. PubMed Akazawa S, et al. 2021. Diabetologia. 64:878. PubMed Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed Sharma M, et al. 2020. Circ Res. 127:335. PubMed Mushaben E, et al. 2011. J Immunol. 187:5756. PubMed Pham D, et al. 2019. Cell Rep. 29:1203. PubMed Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed Gubin MM, et al. 2018. Cell. 175:1014. PubMed Ali S, et al. 2021. PLoS One. 16:e0246646. PubMed Yang Z, et al. 2021. Nat Commun. 12:4852. PubMed Li J, et al. 2022. Nat Commun. 13:4032. PubMed Zeng Q, et al. 2022. iScience. 25:105151. PubMed Takaku S, et al. 2022. Evid Based Complement Alternat Med. 2022:6122955. PubMed Zhang S, et al. 2022. Nat Commun. 13:4744. PubMed Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed He S, et al. 2021. Front Pharmacol. 12:743837. PubMed Kiuchi M, et al. 2021. J Exp Med. 218:. PubMed Chen C, et al. 2020. Cell Rep. 2136:30. PubMed Baglaenko Y, et al. 2016. PLoS One. 11: 0150515. PubMed MaruYama T, et al. 2015. J Leukoc Biol. 98: 385-393. PubMed Wang J, et al. 2019. Aging (Albany NY). 11:3463. PubMed Di Lorenzo A, et al. 2022. Oncoimmunology. 11:2086752. PubMed Blaszczak AM, et al. 2020. Immunometabolism. 2:00. PubMed Singh KS, et al. 2020. Nat Commun. 0.786805556. PubMed Yoshida H, et al. 2019. Cell. 176:897. PubMed Satoh–Takayama N, et al. 2020. Immunity. 52(4):635-649. PubMed Sharma M, et al. 2019. Immunometabolism. 1. PubMed Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed Goldberg EL, et al. 2021. Cell Metabolism. :. PubMed Le TM et al. 2018. Journal of neurochemistry. 145(2):139-153 . PubMed Scott G, et al. 2009. J Immunol. 182:7509. PubMed Tsai S, et al. 2018. Cell Metab. 28:922. PubMed Lee S, et al. 2021. Autophagy. 18:1062. PubMed Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
RRID: AB_961208 (BioLegend Cat. No. 101909) AB_2280288 (BioLegend Cat. No. 101910)
Structure: Forms high affinity IL-2R with IL-2Rβ (CD122) and IL-2Rγ (CD132), 55 kD
Distribution: Activated T cells and B cells, thymocyte subset, pre-B cells, T regulatory cells
Function: IL-2 receptor, signal transduction
Ligand/Receptor: IL-2
Cell Type: B cells, T cells, Tregs
Biology Area: Immunology
Molecular Family: CD Molecules, Cytokine/Chemokine Receptors
Antigen References: 1. Taniguchi T, et al. 1993. Cell 73:5. 2. Waldmann TA. 1991. J. Biol. Chem. 266:2681. 3. Read S, et al. 2000. J. Exp. Med. 192:295. 4. Lowenthal JW, et al. 1985. J. Immunol. 135:3988.
Gene ID: 16184
UniProt: View information about CD25 on UniProt.org
Clone: 3C7
Regulatory Status: RUO
Other Names: IL-2Rα, Ly-43, p55, Tac
Isotype: Rat IgG2b, κ